High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder

TNM Classification of Malignant Tumors

1998 • 5,989 citations

International Histological Classification of Tumours

1981 • 2,045 citations

The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder

1998 • 1,569 citations

Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

2002 • 1,248 citations

MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY

2000 • 1,225 citations

Superficial Bladder Cancer: Progression and Recurrence

1983 • 947 citations

Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer

1992 • 756 citations

A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS

2004 • 733 citations

A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the Bladder

1991 • 605 citations

Intravesical Bacillus Calmette-Guerin Versus Mitomycin C For Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity

2003 • 524 citations

Guidelines on Bladder Cancer

2002 • 471 citations

Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses

2003 • 457 citations

Prognostic Parameters in Superficial Bladder Cancer: An Analysis of 315 Cases

1982 • 434 citations

MULTIVARIATE ANALYSIS OF THE PROGNOSTIC FACTORS OF PRIMARY SUPERFICIAL BLADDER CANCER

2000 • 432 citations

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

2005 • 428 citations

PRIMARY SUPERFICIAL BLADDER CANCER RISK GROUPS ACCORDING TO PROGRESSION, MORTALITY AND RECURRENCE

2000 • 352 citations

Improved Detection of Urothelial Carcinoma In Situ With Hexaminolevulinate Fluorescence Cystoscopy

2004 • 346 citations

EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER

2000 • 314 citations

Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial

2001 • 299 citations

Carcinoma in situ.

1992 • 292 citations

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

2003 • 274 citations

The Relationship Among Multiple Recurrences, Progression and Prognosis of Patients with Stages TA and T1 Transitional Cell Cancer of the Bladder Followed for at least 20 years

1995 • 268 citations

Tumor Markers in the Diagnosis of Primary Bladder Cancer. A Systematic Review

2003 • 268 citations

Phase I Trial of Intravesical Gemcitabine in Bacillus Calmette-Guérin–Refractory Transitional-Cell Carcinoma of the Bladder

2002 • 263 citations

5-YEAR FOLLOWUP OF A RANDOMIZED PROSPECTIVE STUDY COMPARING MITOMYCIN C AND BACILLUS CALMETTE-GUERIN IN PATIENTS WITH SUPERFICIAL BLADDER CARCINOMA

1999 • 252 citations

Intravesical Electromotive Mitomycin C Versus Passive Transport Mitomycin C for High Risk Superficial Bladder Cancer: A Prospective Randomized Study

2003 • 243 citations

Long-Term Effect of Intravesical Bacillus Calmette-Guerin on Flat Carcinoma in Situ of the Bladder

1986 • 233 citations

A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.

1987 • 227 citations

TUMOR PROGRESSION AND SURVIVAL OF PATIENTS WITH HIGH GRADE, NONINVASIVE PAPILLARY (TaG3) BLADDER TUMORS: 15-YEAR OUTCOME

2000 • 214 citations

Stage T1, Grade 3 Transitional Cell Carcinoma of the Bladder: An Unfavorable Tumor?

1987 • 211 citations

Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer

2002 • 205 citations

A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?

2004 • 201 citations

Carcinoma in Situ of the Bladder

1995 • 199 citations

The Value of a Second Transurethral Resection in Evaluating Patients with Bladder Tumours

2003 • 192 citations

THE 3-MONTH CLINICAL RESPONSE TO INTRAVESICAL THERAPY AS A PREDICTIVE FACTOR FOR PROGRESSION IN PATIENTS WITH HIGH RISK SUPERFICIAL BLADDER CANCER

2000 • 189 citations

STAGE PROGRESSION IN TA PAPILLARY UROTHELIAL TUMORS: RELATIONSHIP TO GRADE, IMMUNOHISTOCHEMICAL EXPRESSION OF TUMOR MARKERS, MITOTIC FREQUENCY AND DNA PLOIDY

2001 • 187 citations

Bacillus Calmette-Guerin Versus Doxorubicin Versus Thiotepa: A Randomized Prospective Study in 202 Patients with Superficial Bladder Cancer

1990 • 179 citations

A Randomized Controlled Study of Intravesical α−2b-Interferon in Carcinoma in Situ of the Bladder

1990 • 171 citations

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study.

1988 • 154 citations

Photodynamic Therapy (PDT) in the Treatment of Patients with Resistant Superficial Bladder Cancer: A Long Term Experience

1998 • 151 citations

Natural History of Urothelial Dysplasia of the Bladder

1999 • 150 citations

Survival of patients with carcinoma in situ of the urinary bladder

1999 • 149 citations

Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study

2003 • 141 citations

Single Course Versus Maintenance Bacillus Calmette-Guerin Therapy for Superficial Bladder Tumors: A Prospective, Randomized Trial

1987 • 140 citations

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

2001 • 140 citations

Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study

1995 • 136 citations

Handling and Pathology Reporting of Specimens with Carcinoma of the Urinary Bladder, Ureter, and Renal Pelvis

2003 • 128 citations

Role of 5‐aminolevulinic acid in the detection of urothelial premalignant lesions

2002 • 127 citations

Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder

1995 • 123 citations

THE ROLE AND IMPACT OF PATHOLOGY REVIEW ON STAGE AND GRADE ASSESSMENT OF STAGES TA AND T1 BLADDER TUMORS: A COMBINED ANALYSIS OF 5 EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER TRIALS

2000 • 122 citations

Evaluation and follow-up strategies for superficial bladder cancer

2003 • 116 citations

Fluorescence Detection of Bladder Cancer: A Review

2002 • 114 citations

INTERIM RESULTS FROM A NATIONAL MULTICENTER PHASE II TRIAL OF COMBINATION BACILLUS CALMETTE-GUERIN PLUS INTERFERON ALFA-2B FOR SUPERFICIAL BLADDER CANCER

2004 • 109 citations

Stage Ta-T1 Bladder Cancer: The Relationship Between Findings At First Followup Cystoscopy And Subsequent Recurrence And Progression

2002 • 108 citations

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille calmette-guérin–RIVM and mitomycin c in superficial bladder cancer

1998 • 107 citations

BACILLUS CALMETTE-GUERIN VERSUS EPIRUBICIN FOR PRIMARY, SECONDARY OR CONCURRENT CARCINOMA IN SITU OF THE BLADDER: RESULTS OF A EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER—GENITO-URINARY GROUP PHASE III TRIAL (30906)

2005 • 106 citations

Long-Term Followup of Patients Treated With 1 or 2, 6-Week Courses of Intravesical Bacillus Calmette-Guerin: Analysis of Possible Predictors of Response Free of Tumor

1990 • 103 citations

Bladder Carcinoma in Situ in 2003: State of the Art

2003 • 99 citations

Analysis of early failures after intravesical instillation therapy with bacille Calmette‐Guerin for carcinoma in situ of the bladder

1995 • 98 citations

PHOTODYNAMIC THERAPY USING PORFIMER SODIUM AS AN ALTERNATIVE TO CYSTECTOMY IN PATIENTS WITH REFRACTORY TRANSITIONAL CELL CARCINOMA IN SITU OF THE BLADDER

1998 • 96 citations

RECURRENCE, PROGRESSION AND SUCCESS IN STAGE TA GRADE 3 BLADDER TUMORS TREATED WITH LOW DOSE BACILLUS CALMETTE-GUERIN INSTILLATIONS

2000 • 95 citations

Superficial bladder cancer

2002 • 94 citations

Alternating Mitomycin C and BCG Instillations versus BCG Alone in Treatment of Carcinoma in Situ of the Urinary Bladder: A Nordic Study

2003 • 93 citations

Upper urinary tract involvement in patients with bladder carcinoma in situ (Tis): Its impact on management

1997 • 92 citations

Original Articles

1995 • 92 citations

Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer

2001 • 90 citations

Intravesical BCG in Patients with Carcinoma in situ of the Urinary Bladder: Long–Term Results of EORTC GU Group Phase II Protocol 30861

2001 • 90 citations

Ureteral Carcinoma in Situ After Successful Intravesical Therapy for Superficial Bladder Tumors: Incidence, Possible Pathogenesis and Management

1987 • 90 citations

RESULTS OF A RANDOMIZED PHASE III TRIAL OF SEQUENTIAL INTRAVESICAL THERAPY WITH MITOMYCIN C AND BACILLUS CALMETTE-GUERIN VERSUS MITOMYCIN C ALONE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER

1998 • 89 citations

A Population-based Study of 538 Patients with Newly Detected Urinary Bladder Neoplasms Followed during 5 Years

2003 • 85 citations

Long-term complete remission inbladder carcinoma in situ with intravesical tice bacillus Calmette guerin

1991 • 85 citations

LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER: LONG-TERM RESULTS

2000 • 83 citations

Treatment of Carcinoma In Situ With Intravesical Bacillus Calmette-Guerin Without Maintenance

2002 • 80 citations

Merkel cell carcinoma in situ

2004 • 79 citations

The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial

1994 • 76 citations

Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer

1994 • 71 citations

Photodynamic Therapy for Refractory Superficial Bladder Cancer: Long-Term Clinical Outcomes of Single Treatment Using Intravesical Diffusion Medium

2003 • 69 citations

Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer

1991 • 69 citations

INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES?

1995 • 67 citations

Carcinoma in situ of the urinary bladder. Clues to host involvement in human carcinogenesis

1994 • 65 citations

Initial report on intraves1cal administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder

1997 • 64 citations

The long‐term outcome in patients with superficial transitional cell carcinoma of the bladder: a single‐institutional experience

1999 • 59 citations

Updated concepts and treatment of carcinoma in situ

1998 • 53 citations

Intravesical Thiotepa versus Mitomycin C in Patients with TA, T1 and TIS Transitional Cell Carcinoma of the Bladder: A Phase III Prospective Randomized Study

1988 • 53 citations

Prognostic Significance of Mucosal Aneuploidy in Stage Ta/T1 Grade 3 Carcinoma of the Bladder

1992 • 49 citations

Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Therapy for Carcinoma in Situ of the Bladder

1995 • 49 citations

Risk factors in carcinoma in situ of the urinary bladder

1995 • 49 citations

Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin

1998 • 48 citations

THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER

2001 • 48 citations

Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group.

1995 • 47 citations

SEQUENTIAL BACILLUS CALMETTE-GUERIN AND EPIRUBICIN VERSUS BACILLUS CALMETTE-GUERIN ALONE FOR SUPERFICIAL BLADDER TUMORS: A RANDOMIZED PROSPECTIVE STUDY

1999 • 45 citations

Modified Induction Course: A Solution to Side-Effects?

2000 • 43 citations

Extravesical Involvement in Patients with Bladder Carcinoma In Situ: Biological and Therapy Implications

1996 • 43 citations

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial

1996 • 43 citations

Valrubicin

1999 • 42 citations

CURRENT METHODS OF ASSESSING AND TREATING CARCINOMA IN SITU OF THE BLADDER WITH OR WITHOUT INVOLVEMENT OF THE PROSTATIC URETHRA

1995 • 40 citations

Intravesical Thiotepa and Mitomycin C Treatment Immediately After Transurethral Resection and Later for Superficial (Stages Ta and Tis) Bladder Cancer: A Prospective, Randomized, Stratified Study with Crossover Design

1985 • 39 citations

Intravesical 4′-epi-doxorubicin(epirubicin) versus bacillus calmette—guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer

1993 • 37 citations

Second-line intravesical therapy versus cystectomy for bacille Calmette-Gu??rin (BCG) failures

2004 • 36 citations

The Significance of Central Pathology Review in Clinical Studies of Transitional Cell Carcinoma in Situ

1997 • 35 citations

Clinical Management of Bladder Cancer

1998 • 35 citations

Results of a European Comparative Randomized Study Comparing Oral Bropirimine versus Intravesical BCG Treatment in BCG-Naive Patients with Carcinoma in situ of the Urinary Bladder

1999 • 34 citations

[Carcinoma in situ].

1967 • 30 citations

Effect of Mitomycin C and Doxorubicin Instillation on Carcinoma in situ of the Urinary Bladder

1986 • 22 citations

Carcinoma in situ Associated with Superficial Bladder Tumor

1991 • 21 citations

Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response

1992 • 20 citations

Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette‐Guerin therapy for carcinoma in situ of the bladder

2001 • 19 citations

The significance of tumour grade in predicting disease progression in stage Ta transitional cell carcinoma of the urinary bladder

1996 • 19 citations

Carcinoma in situ of the urinary bladder.

2007 • 15 citations

BCG for Carcinoma in situ

1992 • 15 citations

Bropirimine immunotherapy of upper urinary tract carcinoma in situ

1996 • 14 citations

A Review of Clinical Studies of Bropirimine Immunotherapy of Carcinoma in situ of the Bladder and Upper Urinary Tract

1997 • 13 citations

Use of BCG in Immunotherapy of Superficial Bladder Cancer: Multicentric Investigation on Safety and Compliance

2003 • 13 citations

Evidence-Based Medicine

2006 • 13 citations

Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 Strain) therapy for carcinoma in situ of the bladder: A multivariate analysis

1998 • 11 citations

In vitro evaluation of a novel chemotherapeutic agent, adozelesin, in gynecologic-cancer cell lines

1992 • 10 citations

Fluorescence Detection of Bladder Cancer

1998 • 7 citations

Random trial comparing intravesical chemo-induction with MMC to BCG vs. intravesical BCG, in patients with intermediate-high risk superficial bladder cancer. Efficacy evaluation of CUETO Trial No 93008

2002 • 3 citations

Experimental Research on Endotoxic Shock in Urology

1975 • 3 citations